| |
WOMAC Pain Responder*
|
N
|
Mean Change (FU-Baseline)
|
Std. Deviation
|
Std. Error Mean
|
P-value
|
|---|
|
Interleukin (IL)-7
|
No
|
23
|
0.084
|
0.91
|
0.19
|
0.01
|
|
Yes
|
12
|
1.07
|
1.17
|
0.34
| |
|
IL-10
|
No
|
23
|
8.51
|
20.90
|
4.36
|
0.01
|
|
Yes
|
12
|
27.72
|
21.56
|
6.22
| |
|
IL-12 p70
|
No
|
23
|
3.36
|
8.17
|
1.70
|
0.004
|
|
Yes
|
12
|
12.91
|
9.60
|
2.77
| |
|
Eotaxin
|
No
|
23
|
−2.03
|
13.92
|
2.90
|
0.046
|
|
Yes
|
12
|
7.85
|
12.28
|
3.54
| |
|
Interferon gamma (IFN-γ)
|
No
|
23
|
−1.24
|
23.18
|
4.83
|
0.03
|
|
Yes
|
12
|
15.61
|
13.35
|
3.85
| |
|
Tumor necrosis factor-alpha (TNF-α)
|
No
|
23
|
4.46
|
21.32
|
4.44
|
0.03
|
|
Yes
|
12
|
22.22
|
24.65
|
7.12
| |
|
IL-4
|
No
|
23
|
−0.02
|
0.16
|
0.03
|
0.12
|
|
Yes
|
12
|
0.06
|
0.12
|
0.03
| |
|
IL-6
|
No
|
23
|
−15.90
|
275.66
|
57.48
|
0.09
|
|
Yes
|
12
|
137.35
|
182.09
|
52.56
| |
|
IL-13
|
No
|
23
|
4.90
|
13.25
|
2.76
|
0.15
|
|
Yes
|
12
|
12.18
|
14.87
|
4.29
| |
|
IL-15
|
No
|
23
|
0.31
|
11.87
|
2.47
|
0.09
|
|
Yes
|
12
|
7.36
|
10.52
|
3.038
| |
|
Macrophage Inflammatory Protein-1 beta (mip1b)
|
No
|
23
|
5.55
|
91.43
|
19.06
|
0.16
|
|
Yes
|
12
|
53.35
|
96.39
|
27.82
| |
|
Substance P
|
No
|
14
|
0.08
|
1.11
|
0.298
|
0.32
|
|
Yes
|
5
|
−0.46
|
0.61
|
0.273
| |
- Only those associations that either had a significant p-value or a p-value <0.33 are listed; The levels of other cytokine did not differ significantly between pain responders and pain non-responders (IL-1 beta, IL-1 alpha, IL-2, IL-5, IL-8, IL-9, IL-17, Basic FGF, G-CSF, GM-CSF, IP-10, MCP-1, MIP-1 alpha, PDGF, RANTES, and VEGF). Significant p-values <0.05 are in bold
- Positive changes mean that at the 2-month follow-up time, the levels were higher than the baseline and a negative sign means follow-up levels were lower
- WOMAC Pain Responder* is defined as reduction in WOMAC pain subscale of 20 or more 0–100 scale
